INTRODUCTION
Bioisosteres were originally defined as molecules or functional groups that have similar chemical and physical properties and that hence exhibit similar biological activities [1, 2] . This definition has since been extended to include substructural features that are structurally different but that can form similar intermolecular interactions. The concept of bioisosterism is an important approach in the lead-optimisation stage of a drug-design programme as it provides a way of enhancing some desirable chemical or physical property, e.g. to improve solubility or metabolic stability, whilst still maintaining the biological activity of interest [3] .
For example, Merderski et al. reported the use of the benzothiadiazole group as a bioisoster for the methylendioxyphenyl group in a study of endothelin receptor antagonists [4] ; Uddin et al. described the use of the sulfonylazide group as a booster for the sulphonamide group in a study of celecoxib analogues [5] ; and Showell and Mills advocated the use of silicon as a replacement for a fully substituted sp 3 carbon [6] . The use of bioisosterism to support lead optimisation will also be the focus of the work reported here. It is, however, worth noting that there is now also increasing interest in the use of scaffold-hopping techniques to suggest replacement ring systems that can locate functionality at the appropriate locations in 3D space whilst providing a novel patent position (see, e.g., [7] [8] [9] ).
A convenient source of bioisosteres is the BIOSTER database from Accelrys Inc., which details pairs of compounds that have been reported in the literature as being biologically interchangeable [10] . The current version of the database, Version 2003.1, contains almost eleven-thousand pairs of potential bioisosteres, including drugs, agrochemicals and enzyme inhibitors [11] . Alternatively, means can be found to identify bioisosteres automatically and a range of approaches have been described that are based on calculating measures of similarity between pairs of substituents to find those that are closely related using the chosen similarity measure. Then, given an existing bioactive molecule, potential analogues are obtained by replacing one or more of the substituents on a central scaffold by those substituents that have previously been shown to be most similar. There have been several reports of such techniques, differing principally in the types of information that are used for the calculation of the inter-substituent similarities.
The simplest way of measuring the similarity between a pair of substituents uses the 2D fingerprint measures that are widely used for similarity searching in chemical databases.
Such an approach has been reported recently by Wagener and Lommerse, who describe a system that has been developed at Organon for suggesting bioisosteric replacements and that is based on fingerprints encoding topological pharmacophore information about the atoms comprising a substituent [12] . In another topology-based study, Sheridan analysed pairs of molecules that belonged to the same activity class in the MDL Drug Data Report (MDDR) database and that differed in only one location [13] . Use of a maximum common substructure algorithm identified the common parts of the two molecules that were being compared; this common substructure was removed and the remaining pair of substructures stored as potential bioisosteres. Some of the replacements were generic, in that they occurred frequently throughout the MDDR, while others were identified only within specific therapeutic classes.
A focus on the identification of topological equivalences inevitably means that less account is taken of physicochemical properties that may be of particular importance in the context of bioactivity. Both Ertl et al. [14] and Holliday et al. [15] have reported work in which a substituent is characterised by computed physicochemical properties of various sorts. The first of these represents a substituent by a vector of properties that are computed for the substituent as a whole; related ideas have been reported recently by Zhu et al. in work on the measurement of superstructure similarity in the design of reaction schemes [16] . The more complex system described by Holliday et al. represents a substituent by a series of vectors that encode the sum of the atomic properties at increasing numbers of bonds away from the point of attachment of the substituent. The more detailed representation thus takes account of both the physicochemical characteristics of a substituent and its topology (and, implicitly, of its geometry in the case of low-flexibility substituents). The resulting similarities have been used successfully for both database searching and QSAR [15, 17] .
Finally, there is IsoStar, which is a knowledge base containing information on the geometries of non-bonded interactions between specified pairs of chemical groups [18, 19] . The geometric data is used to generate scatterplots showing all the possible positions of a chosen contact group around a chosen central group, thus providing an overview of the preferred orientations that allow a particular group-to-group interaction to take place. Watson et al.
have discussed geometric similarity measures based on these scatterplots, so as to identify groups that are oriented similarly with respect to a given central group, such as a key amino acid in a protein active site [20] . This study is perhaps the most closely related to the work reported here in that both approaches use X-ray crystallographic data as the basis for identifying pairs of similar substructures; however, our work identifies equivalences that are specific to a particular target, and that are hence more likely to be associated with changes in the biological activity of interest.
METHODS

Introduction
Our techniques seek to identify potential bioisosteres within a set of ligands for a particular protein target. In brief, each ligand within a dataset is chosen in turn to act as the reference ligand, which is then compared to all the other ligands in the dataset, each of which is referred to as a query ligand. The query ligand is split into a set of fragments (the query fragments) to identify small regions within a pair of ligands that might be bioisosteric. The potential bioisosteres are identified based on volume overlap between a query fragment and a region within the current reference ligand that occupies the same space as the query fragment. The procedure is summarised in Figure 1 , and explained in greater detail in the remainder of this section. The majority of the software was written using the Scientific Vector Language (SVL) scripting language available in the Molecular Operating Environment (MOE) that has been developed by the Chemical Computing Group [21] .
Alignment and splitting of the ligands
The Protein Data Bank (PDB) was searched to retrieve sets of structures that all shared a common amino acid sequence and that all contained a ligand bound to the protein [22] . One combinations, and this set of fragments is then filtered to remove those that contain just a single atom, e.g., the single nitrogen atom fragment in Figure 3 .
Identification of fragment pairs
Each query fragment is then compared with the current reference molecule to identify the reference-molecule atoms that best overlay the query fragment. The fragment and the reference molecule are already aligned, and it is hence simple to score the overlaps between the query fragment and sections of the reference molecule to determine the best mapping.
The mapping is based on the degree to which the two fragments overlap in terms of the volume of their constituent atoms. Fragments with a high degree of overlap will occupy a similar position within the protein's active site and are hence assumed to have a similar role within the ligand.
Scoring reference molecule sections
As mentioned previously, the best overlap of each query fragment with the reference molecule needs to be identified, the resulting overlap being called the reference fragment. In order to do this, the reference molecule is split into sections, where a section is defined as respectively. An average score is calculated by dividing this value by the number of atoms within the section, and the resulting mean score used to determine whether this section should be included within the reference fragment: this is done if the mean score is at least 0.5. This procedure is illustrated in Figure 5 , comparing the same reference molecule as in Figure 4 with a query fragment shown in orange. Here, two of the five sections of the reference molecule score highly enough, compared to the query fragment, to be included in the reference fragment (as indicated by the ticks), but the other three are omitted (as indicated by crosses). The two selected sections in Figure 5 hence comprise the fragment pair shown in Figure 6 , with the two substructural moieties making equivalent hydrogen bonding interactions with the protein structure.
Calculating the average overall score
Once the fragment pair has been identified then an average overall score for the pair needs to be calculated: this score is used to determine whether the fragment pair should be saved and Fragment pairs scoring less than a cut-off value 0.7 are excluded from further consideration, thus removing poorly aligned fragment pairs. In addition, a series of filters was applied so as to remove fragment pairs that could not meet one or more of several criteria that are necessary for a fragment pair to represent a potential bioisosteric pair [23] . Examples of such criteria include the following. First, only query fragments containing 20 atoms or less and reference fragments containing more than one atom are considered. Second, it is possible for the query fragment and the reference fragment to be identical (especially if the ligands in the dataset have structurally similar regions to each other); these pairs are obviously not bioisosteric and are hence also removed. Third, disjointed reference fragments were removed: these arise when the sections of the reference molecule that scored highly enough to be part of the reference fragment were not all connected together within the 6 reference molecule.
RESULTS AND DISCUSSION
The procedure described above was run on several sets of ligands drawn from the PDB, as listed in Table 1 . It will be seen from this table that there are major variations in the numbers of distinct fragment pairs identified. The number depends on several factors, including: the number of ligands within the dataset; whether the ligands all bind to the same active site within the protein (and hence occupy a similar space); and the structural diversity of the ligands (as structurally homogeneous ligands are likely to produce multiple nonunique fragment pairs). Even so, the procedure is sufficiently rapid in execution to enable datasets of the sort shown in Table 1 to be processed in 5-10 minutes on a Linux PC.
Examples of the fragment pairs identified are shown in One of the principal applications of bioisosteres during lead optimisation is to enhance a molecule's ADMET profile. There is hence a need to link the substructural equivalences identified here with locally-generated physicochemical data. Specifically, the data is scanned to find pairs of molecules that differ from one another just by that particular fragment pair. The property data associated with such a molecule-pair is then used to compute ΔP, where P is the altered property. The procedure is repeated for all moleculepairs with the chosen fragment-pair and the mean ΔP computed, so as to identify substituent replacements that are expected to improve the chosen property P. A prototype system based on these ideas is now under development at Sanofi-Aventis.
CONCLUSIONS
There is a rapidly increasing number of ligand-protein complexes for which X-ray crystallographic data are available, with many important biological targets for which there are complexes with a range of different ligands. The availability of such data provides a basis for the identification of bioisosteres that are target-specific. The resulting bioisosteres might be expected to provide more reliable information when modifying an existing lead compound than do existing approaches, which are based either on empirical measures of inter-substituent similarity or on non-target-specific crystallographic data. In this paper, we Extract a set of ligands from the PDB that are all complexed with the same protein.
Align the ligands on the basis of the common protein structure. Starred examples are shown in Figure 9 .
